A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Part of paid clinical trials in Aurora, Colorado.
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Study ID
- NCT07218146
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Small-cell Lung Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ZL-1310 — DRUGZL-1310 as a single-agent
- Investigator's Choice of Therapy — DRUGTopotecan, Lurbinectedin, or Amrubicin
Study Details
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Key Dates
- Start date
- Nov 30, 2025
- Status verified
- May 2026
- Primary completion
- Jun 30, 2028
- Completion
- Nov 30, 2028
Study Design
- Enrollment
- 480 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm 1ZL-1310 as a single agent
- Active Comparator: Arm 2Investigator's Choice of Therapy
Primary Outcome Measure
Confirmed objective response rate (ORR) assessed by Blinded Independent Central Review of ZL-1310 compared to Investigator's Choice Therapy (ICT) [ Time Frame: up to 27 months ]
Central Contacts
- ZL-1310-003 Study Team(510)-316-3502
Locations (28)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Zai Lab Site 02037 | Aurora | Colorado | 80045 | - |
| Zai Lab Site 02030 | New Haven | Connecticut | 06519 | - |
| Zai Lab Site 02045 | Clermont | Florida | 34711 | - |
| Zai Lab Site 02031 | Orange City | Florida | 32763 | - |
| Zai Lab Site 02020 | Rockledge | Florida | 32955 | - |
| Zai Lab Site 02026 | Sarasota | Florida | 34232 | - |
| Zai Lab Site 02052 | St. Petersburg | Florida | 33701-4553 | - |
| Zai Lab Site 02051 | West Palm Beach | Florida | 33401 | - |
| Zai Lab Site 02021 | Peoria | Illinois | 61615 | - |
| Zai Lab Site 02049 | Peoria | Illinois | 61637 | - |
| Zai Lab Site 02038 | Iowa City | Iowa | 52242 | - |
| Zai Lab Site 02041 | Louisville | Kentucky | 40202 | - |
| Zai Lab Site 02003 | Bethesda | Maryland | 20817 | - |
| Zai Lab Site 02022 | Silver Spring | Maryland | 20904 | - |
| Zai Lab Site 02010 | Detroit | Michigan | 48202 | - |
| Zai Lab Site 02023 | Columbia | Missouri | 65201 | - |
| Zai Lab Site 02009 | St Louis | Missouri | 63128 | - |
| Zai Lab Site 02040 | The Bronx | New York | 10461 | - |
| Zai Lab Site 02024 | Cleveland | Ohio | 44106 | - |
| Zai Lab Site 02035 | Broomall | Pennsylvania | 19008 | - |
| Zai Lab Site 02019 | Media | Pennsylvania | 19063 | - |
| Zai Lab Site 02008 | Pittsburgh | Pennsylvania | 15212 | - |
| Zai Lab Site 02029 | Pittsburgh | Pennsylvania | 15232 | - |
| Zai Lab Site 02036 | Nashville | Tennessee | 37203 | - |
| Zai Lab Site 02025 | Austin | Texas | 78745 | - |
| Zai Lab Site 02046 | Dallas | Texas | 75390-9020 | - |
| Zai Lab Site 02025 | Odessa | Texas | 79761 | - |
| Zai Lab Site 02006 | Fairfax | Virginia | 22031 | - |
Find similar trials in Aurora, CO
Related Studies
- Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)PHASE2 · Recruiting · University of Chicago · Chicago, Illinois
- A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the BrainPHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung CancerPHASE2 · Recruiting · University of Maryland, Baltimore · Baltimore, Maryland
- Dose Attenuated Chemotherapy in Compromised Patients With Lung CancerPHASE2 · Recruiting · Fox Chase Cancer Center · Philadelphia, Pennsylvania